T Lymphocyte-Based Cancer Immunotherapeutics

Area of Science:

• Oncology
• Immunology
• Cancer Therapeutics

Background:

• Immunotherapy has emerged as a significant advancement in cancer treatment over the last decade.
• It empowers the immune system to target and eliminate cancer cells, transforming cancer management.
• Significant progress has been made in immune checkpoint inhibitors, adoptive cell therapy, and oncolytic viruses.

Purpose of the Study:

• To review approved and investigational immunotherapeutics for cancer treatment.
• To highlight therapies that directly engage T-cells or activate T-cells.
• To discuss the impact of these therapies on late-stage cancer patients.

Main Methods:

• Review of current literature on cancer immunotherapy.
• Discussion of T-cell-centric approaches like chimeric antigen receptor T-cells and checkpoint inhibitors.
• Exploration of T-cell-activating strategies, including oncolytic viruses.

Main Results:

• Immunotherapies have demonstrated exceptional and durable clinical responses in patients with advanced cancer.
• Approved and investigational agents are transforming the treatment landscape.
• These therapies offer new hope for patients with limited options.

Conclusions:

• Immunotherapy is a powerful modality for cancer treatment.
• T-cell-based immunotherapies and T-cell-activating agents are key components of modern cancer care.
• Continued research and development promise further advancements in harnessing the immune system against cancer.